Integra LifeSciences (IART) is a ≈$0.9B medical device company — 70% neurosurgery and ENT (Codman Specialty Surgical), 30% wound care (Tissue Technologies). Stock is down 30% over the past year but up 21% in the last month on a recovery from $8.70 to $11.03. An 8-K filed April 15, 2026 extended a $150M accounts receivable facility to 2029 — routine housekeeping. The reason to look at the name now is that it closes out a four-filing sequence: FDA warning letter (Dec 2024), covenant relief amendment (Jun 2025), CIC severance program renewal with a Dec 31, 2026 expiration (Dec 2025), A/R extension (Apr 2026).

What the filings say

The June 2025 covenant relief amendment (8-K 2025-06-09, Item 1.01) maintained the 5.00x maximum Consolidated Total Leverage Ratio through Q2 2026, stepping down to 4.75x Q3 2026, 4.50x Q4, and 4.00x Q1 2027+. During the Covenant Relief Period — through delivery of FY2026 financials — lenders imposed restrictions: no M&A leverage step-ups, restricted payments limited, IP licensing to non-loan-party subsidiaries prohibited, incremental debt restricted, higher applicable rate schedule. The 10-K (2026-02-26) reports actual leverage of 4.50x at Dec 31, 2025 — 50bps under ceiling today, but the ceiling drops to 4.75x in two quarters.

The December 2025 CIC Severance Program (8-K 2025-12-12, Item 5.02) was adopted effective January 1, 2026 with expiration December 31, 2026. It renews a prior program that expired December 31, 2025; the 12-month horizon matches the prior program's structure, so the renewal itself is not unprecedented. CFO Knight receives 2x (base + target bonus); division EVPs Davis (TT), McBreen (CSS), and Singh (International) receive 1.5x. The qualifying CIC event must occur within the window.

The filings don't interpret themselves, but one reading: the Covenant Relief Period restricts IART from acting as an acquirer (no M&A leverage step-ups, no IP transfers to non-loan-party subs), while nothing prevents a third-party buyer from taking out the company and refinancing the debt. The CIC window closes at a date coincident with that possibility.

Stryker is the most proximate acquirer candidate. IART's 10-K names Medtronic, Stryker, Steris, and B. Braun as CSS competitors. Stryker CEO Kevin Lobo on the Q4 2025 call: "constant tuck-ins" playbook and "larger deals value company." SYK Neuro Cranial US organic sales grew 12.9% in Q3 2025 — close adjacency to IART's neurosurgery franchise, and SYK has the balance sheet to absorb a $0.9B target. I.C.U. Medical (ICUI) offers a precedent for the FDA timeline: Smiths Medical warning letter inherited pre-2022, closed Q4 2025, ≈24-36 month resolution. IART's warning letter issued December 2024 — a 24-month resolution window lands in December 2026, coincident with the CIC expiration.

What the market thinks

Forward P/E 4.31x. Stock at 26% of 52-week range. Short interest 17.4% of float with 10.4 days to cover. JPMorgan named IART a top Q1 2026 short. Argus downgraded to Hold the day before the 8-K filed, citing quality control. Mean analyst target $15.43, median $12.00. Options open interest is near zero across all strikes — no takeout premium is priced.

Backing out the implied takeout probability. Assume the standalone muddle-through value is ≈$11 (matches current) and a strategic takeout would clear at roughly $24 (2.5x sales on ≈$1.6B revenue = $4B EV, less ≈$1.6B net debt, = ≈$24/sh): $$11.03 ≈ 11 + P_{market}·(24 - 11) → P_{market} ≈ 0-3%$$

Our five-state scenario at Dec 31, 2026: takeout 28% ($24), clean standalone 18% ($17), muddle through 34% ($11), partial stress 12% ($7.50), breach/dilution 8% ($4). Weighted fair value $14.75 — +34% over 8 months. The entire gap is in the takeout state. At P(takeout) = 15% our fair value is $12.60; at P(takeout) = 40% it is $16.70. The 15-52% upside band is the honest uncertainty range, and it's driven almost entirely by one probability.

Why the gap exists

Item 5.02 (compensation) is less-read than Item 1.01 (material contracts). The lender carve-out that leaves IART sellable-but-not-buyer requires reading the June 2025 amendment alongside the December 2025 CIC renewal. The ICUI precedent is a cross-ticker read-through that sell-side on IART hasn't synthesized. Ten analysts cover the name; three rate it Sell. No activist has filed 13D/13G. No options activity signals a specific event. The consensus read is distressed operator with covenant risk — the strategic-option reading requires assembling four filings across three quarters.

Risks, ranked

1. Covenant breach — 4.50x actual vs 4.75x ceiling by Q3 2026, 25bps of headroom, Q1 seasonally weakest. Breach would force equity dilution at discount or restructuring. Our probability: 15%.
2. CIC renewal is routine. The program renewed a prior identical-horizon program; the matching 12-month window could be administrative rather than signaling. Without the lender carve-out, the signal is weak.
3. No activist presence. Zero 13D/13G filings. "Board-engineered optionality" does not equal "live process." No forcing function for the thesis to resolve bullishly before the CIC expiration.
4. FDA remediation drags longer than ICUI. Three facilities multiplies complexity vs. ICUI's single-site precedent.
5. Q1 2026 EBITDA miss compresses covenant headroom ahead of the Q3 step-down.

Catalysts

• May 4, 2026 — Q1 2026 earnings (after close). EBITDA vs covenant, WL update, any strategic language.
• August 2026 — Q2 earnings.
• October/November 2026 — Q3 earnings tests 4.75x covenant compliance.
• December 31, 2026 — CIC program hard expiration.
• Q1 2027 — covenant drops to 4.00x permanent.
• Anytime: 13D/13G filing; call OI accumulation at $12.50/$15 June/September strikes; SYK or MDT earnings naming neurosurgery tuck-ins by size.

What would change our mind

Toward bull: 13D/13G filing; call OI appearing at $12.50/$15 Jun/Sep expirations; FDA Phase 1 closure (1 of 3 facilities); SurgiMend or DuraSorb PMA approval; SYK commentary naming neurosurgery tuck-ins by size; another insider open-market purchase.

Toward bear: Amendment No. 2 with stricter terms; covenant breach 8-K; going-concern audit modification; FDA consent decree; CFO or CEO departure; Board public commitment to standalone plan.

Evidence

Geo mean LR across stack: 0.93 — net neutral-to-mildly-bearish on standalone fundamentals. Bull signals (CIC renewal, SYK proximity, ICUI precedent, Singh purchase) offset bear signals (FDA, covenant, leverage) to roughly flat. The thesis relies on one observation: market-implied P(takeout) ≈ 0-3%, our estimate ≈ 28%.